Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

We'll know more about the company's medium-term prospects by the end of the year.

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

Mon, August 4, 2025 at 11:15 AM UTC Viking Therapeutics (NASDAQ: VKTX) represents exactly this type of overlooked opportunity, trading at a valuation of just $3.7 billion as of Aug. 1, despite owning ...

Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year pipeline ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.